GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.
about
GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
GTL001, a bivalent therapeutic ...... s leading to tumor regression.
@ast
GTL001, a bivalent therapeutic ...... s leading to tumor regression.
@en
type
label
GTL001, a bivalent therapeutic ...... s leading to tumor regression.
@ast
GTL001, a bivalent therapeutic ...... s leading to tumor regression.
@en
prefLabel
GTL001, a bivalent therapeutic ...... s leading to tumor regression.
@ast
GTL001, a bivalent therapeutic ...... s leading to tumor regression.
@en
P2093
P2860
P1433
P1476
GTL001, a bivalent therapeutic ...... s leading to tumor regression.
@en
P2093
Anne Goubier
Astrid Navarro
Christophe Gonindard
Hélène Keller
Marie Momot
Michaël Esquerré
Myriam Bouillette-Marussig
P2860
P304
P356
10.1371/JOURNAL.PONE.0174038
P407
P577
2017-03-16T00:00:00Z